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Word of Welcome
On behalf of the EHA Board and the Scientific Program Committee of the 21st Congress of EHA we are
pleased to introduce this year’s Abstract Program.
The Scientific Program Committee has compiled an exciting up-to-date program of Simultaneous Oral
and Poster Sessions from over 2400 abstracts submitted. Selected posters will be presented during the
traditional Poster Walks allowing more time for discussion of results and conclusions. To better pro-
mote basic research in hematology, we introduced a new special presentation type: the poster pitch!
During selected oral sessions, 5-8 presenters will have the opportunity to pitch their abstract/poster to
the attendees of the session.
There are also E-posters available on the E-poster screens, for which a specific time is allocated dur-
ing the Poster Browsing Time at the end of each Walk. All presented posters and E-posters can be
viewed on the E-poster screens from Friday morning to Saturday evening. Posters will also be available
on the EHA Learning Center, for which you have complimentary access after the congress: learningcen-
ter.ehaweb.org.
The six Best Abstracts will be presented during the Presidential Symposium on Friday afternoon. One
of them has been selected from the record number of “late breaking abstracts” with “hot” data. Only the
most exciting results have been selected and will be presented in the Late Breaking Oral Session on
Sunday morning. There are also late breaking posters that are included in a poster walk of the relevant
topic. 
On behalf of the EHA Board, the committees and all the people involved in this years’ EHA congress,
we thank you for coming to Copenhagen and wish you an exciting meeting.
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PAROXYSMAL NOCTURNAL HEMOGLOBINURIA SCREENING PRACTICE
FROM UK CENTRES: A REPORT FROM THE UK PNH NETWORK
M Griffin1,*, C Couzens2, W Ingram2, R Karim2, M Koh3, M Layton4, K Lowndes5,
M McMullin6, P Medd7, L Mitchell8, L Morgan2, S Narayanan9, I Neilly10,
M Nikolousis11, J Ros12, N Sharma6, A Hill1
1Hematology, Leeds teaching hospitals, Leeds, 2Hematology, University Hospital
of Wales, Cardiff, 3Hematology, St Georges Hosptial and Medical School, 4Hema-
tology, Hammersmith hospitals, London, 5Hematology, Hampshire Hospitals NHS
foundation trust, Winchester, 6Hematology, Centre for cancer research and cell
biology, Belfast, 7Hematology, Plymouth Hospitals NHS trust, Plymouth, 8Hema-
tology, NHS Lanarkshire, Lanarkshire, 9Hematology, University hospital
Southampton, Southampton, 10Hematology, Northumbria healthcare trust,
Northumbria, 11Hematology, Heart of England NSH trust, Birmingham, 12Hema-
tology, St Georges Hospital and Medical School, London, United Kingdom
Background: Paroxysmal Nocturnal Hemoglobinuria (PNH) is an acquired
clonal stem cell disorder with an associated complement mediated morbidity
and mortality. International flow cytometry guidelines recommend PNH screen-
ing in ‘at risk’ patients. These include patients with bone marrow failure syn-
dromes; Intravascular hemolysis; unexplained hemolysis with iron deficiency,
oesophageal spasm, thrombocytopenia or granulocytopenia; unusual throm-
bosis with unexplained cytopenia or hemolysis; or other acquired direct coomb’s
test negative hemolytic anaemias. 
Aims: The aim of this retrospective audit is to determine application of the
International flow cytometry guidelines in UK practice. 
Methods: The UK PNH network members (hematologists with an interest in
PNH) provided anonymised data for analysis. PNH screens analysed from Jan-
uary 2014 to December 2014 were included.
Results: 1579 PNH screens were assessed (53% male; mean age 53 yrs), of
which 9.4% were positive. Screening indications included aplastic anaemia (AA)
(5.3%) of which 40% were positive, cytopenias (36.7%) of which 11% were pos-
itive, thrombosis (28%) of which 2% were positive, haemolysis (5.7%) of which
12% were positive, MDS (0.4%) of which 6% were positive, and other reasons
(6.9%) with 6% positive. 257 (16%) screens had no clinical details provided. PNH
clone size varied with the majority less than 1% (53%). 22% had a clone size of
1-10%, and 12% had a clone of 10-50%. 18 (12%) had a clone of more than
50%, of these 5 were screened for haemolysis, 7 cytopenias, 4 no clinical details,
1 thrombosis and 1 AA. 377 patients with repeat testing were assessed, 91% of
whom had a known PNH clone. The majority had clinical PNH (218), of whom
25% had evolved from preceding AA and 3% from MDS. 
Summary/Conclusions: This is the largest audit of PNH screening requests
from UK centres. It’s reassuring that recommendations are adhered to with
very few patients screened inappropriately. 40% of AA patients had a PNH
clone in keeping with current evidence. The subgroup analysis highlights the
importance of PNH clone monitoring in patients with underlying bone marrow
disorders, as they may subsequently develop clinical PNH and require treat-
ment. Ongoing education is essential for the screening and monitoring for this
rare but potentially fatal disease. 
Disclosure: Alexion UK provided funding to support the UK PNH network
meetings.
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